Rays of Belief, the parent company of Mom's Belief, has raised ₹50 crore through an anchor book allocation. The firm’s ₹125 crore initial public offering opens on September 1, with a price band set at ₹227–₹239 per share.
Rays of Belief, the parent entity behind the therapy and intervention service provider Mom's Belief, has successfully completed its anchor investor round. The company raised ₹50 crore on August 31, 2026, ahead of its upcoming initial public offering (IPO). The anchor allocation saw participation from five institutional investors, including Viney Growth Fund, LRSD Securities, Nova Global Opportunities Fund, 31 Degrees North Fund, and Visionary Value Fund. These shares were allotted at the upper end of the price band, which is ₹239 per share.
The public offering aims to raise ₹125 crore through a fresh issue of 52.3 lakh shares. The IPO will open for subscription on September 1, 2026, and will conclude on September 3, 2026. Shares are expected to list on the stock exchanges on September 8, 2026.
Business Strategy and Expansion
Rays of Belief specializes in providing services for children with neurodevelopmental disorders under the Mom’s Belief brand. The company intends to use the capital raised from this IPO to fund a significant expansion of its operational footprint. A major portion of the proceeds is earmarked for establishing 319 new centers across India. Additionally, the company plans to invest in hardware and technology infrastructure to support its service delivery. A share of the funds is also allocated to lease obligations for its existing Indian facilities and its subsidiary, Mom’s Belief US Inc., to support international leasing requirements.
Financial Context and Risks
For the financial year 2026, the company reported a consolidated revenue of ₹81.66 crore and a profit after tax of ₹4.96 crore. While the company is expanding, investors may note that this is a niche segment in the healthcare space. The business model involves significant execution risk, as scaling a large network of centers requires maintaining service quality and navigating complex healthcare and therapy licensing regulations.
Furthermore, some market analysts have pointed to the company’s valuation relative to its current earnings, which is a factor to consider given the modest profit margins. The business also carries a degree of concentration risk, given its reliance on specialized therapy services and the need to maintain regulatory compliance across multiple jurisdictions. The success of the expansion will depend on the company's ability to drive demand in a market that still faces social and cultural stigma regarding neurodevelopmental disorders. Investors tracking the stock may monitor the subscription levels and the management's ability to execute its aggressive expansion plan over the coming quarters.